logo-loader
LON:SUMM

Summit Therapeutics PLC

Receive alerts
Market:
LON
Market Cap:
£30.49 m
Price
£0.19
Change
-5.00%
52 weeks high
39.00
52 weeks low
9.50

In brief

Summit Therapeutics is a leader in antibiotic innovation. Summit’s new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. The company is currently developing new mechanism antibiotics for infections caused by C. difficile, N. Gonorrhoeae and ESKAPE pathogens and is using its proprietary Discuva Platform to expand its pipeline.

Insight

Research

Summit Therapeutics Plc - Stock Valuation Undemanding

- Key inflection point: topline data readout from the PhaseOut DMD phase 2 trial in Duche...

on 3/4/18